KMT2A and leukemia: BCL-2 has been previously implicated in the pathogenesis of MLLr leukemias, and disruption of MLL-fusion-driven BCL-2 expression has been proposed as a major mechanism of action for the bromodomain inhibitor I-BET151 (Dawson et al., 2011).